| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000016362 |
| Receipt No. | R000018999 |
| Official scientific title of the study | Effects of OTC switching on prescription trends of ethical drugs |
| Date of disclosure of the study information | 2015/01/30 |
| Last modified on | 2018/06/18 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Effects of OTC switching on prescription trends of ethical drugs | |
| Title of the study (Brief title) | Effects of OTC switching on prescription drugs | |
| Region |
|
|
| Condition | ||
| Condition | Hay fever, Hyperlipidemia, Pain | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Investigate the effects of OTC switching on prescription trends of original ethical drugs using a nation-wide pharmacy claims database. |
| Basic objectives2 | Others |
| Basic objectives -Others | Drug utilization |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Regional, monthly trends in prescription and prescribed patients before and after OTC switching. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients despensed with the study prescription drugs | |||
| Key exclusion criteria | Not applicable | |||
| Target sample size | 100000 | |||
| Research contact person | |
| Name of lead principal investigator | Hisashi Urushihara |
| Organization | Keio University, Faculty of Pharmacy |
| Division name | Drug Dev. Regulartory Sci, |
| Address | 1-5-30, Shiba-koen, Minato-ku, TOKYO, JAPAN |
| TEL | +81354002649 |
| urushihara-hs@pha.keio.ac.jp | |
| Public contact | |
| Name of contact person | Keio University |
| Organization | Keio University, Faculty of Pharmacy |
| Division name | Drug Dev. Regulartory Sci, |
| Address | 1-5-30, Shiba-koen, Minato-ku, TOKYO, JAPAN |
| TEL | +81354002649 |
| Homepage URL | |
| urushihara-hs@pha.keio.ac.jp | |
| Sponsor | |
| Institute | Keio University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Keio University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | |
| Results | Manuscript have been developed and publication process ongoing. |
| Other related information | Drug utilization study using a commercial pharmacy claims database run by IMS Japan, which consists of pharmacy claims data accumulating 53 million prescriptions annually from more than 3000 dispensing pharmacies out-of-hospital beginning from January 2008, accounting for 6.9% of the total national prescriptions.
The study ethical drugs are selected as ones whose OTC-switched drugs started to be sold within the study period and allowing sufficient pre-switching period for evaluating trend changes, including troxipide, loxoprofen sodium hydrate, mequitazine, epinastine hydrochloride, pemirolast, fexofenadine hydrochloride, cetirizine hydrochloride, and ethyl icosapentate. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018999 |